Login to Your Account

Sanofi buys into Medimmune's next-gen RSV antibody franchise

By Cormac Sheridan
Staff Writer

Friday, March 3, 2017

DUBLIN – Sanofi SA is paying €120 million up front and could pay up to €495 million more in development and commercial milestones for a 50 percent share in the economics of Astrazeneca plc's MEDI8897.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription